Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00363857 · ClinicalTrials.gov registry record · Phase 3

A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome

A Phase 3 study of Restless Legs Syndrome and Restless Legs Syndrome (RLS), sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 3
Development phase
360
Enrollment target
20
Study locations

NCT00363857: Completed Phase 3 study of Restless Legs Syndrome and Restless Legs Syndrome (RLS), sponsored by GlaxoSmithKline.

NCT00363857 is a Phase 3 study of Restless Legs Syndrome and Restless Legs Syndrome (RLS) that has completed, run by GlaxoSmithKline. The registered enrollment target is 360 participants, above the 71-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (407% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00363857, a Phase 3 study of Restless Legs Syndrome and Restless Legs Syndrome (RLS), has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 3
Development phase
360 participants
Enrollment target
20
Study locations

Study Summary

A 14-Week clinical research study to compare the effectiveness and safety of ropinirole and placebo (an inactive sugar pill) in the treatment of patients with Restless Legs Syndrome (RLS) in the United States.

Interventions

  • DRUG Ropinirole

Study Locations (20)

California

  • GSK Investigational Site - Berkeley
  • GSK Investigational Site - La Jolla
  • GSK Investigational Site - Northridge
  • GSK Investigational Site - Oxnard
  • GSK Investigational Site - Redondo Beach
  • GSK Investigational Site - Santa Monica
  • GSK Investigational Site - Stanford

Alabama

  • GSK Investigational Site - Alabaster
  • GSK Investigational Site - Birmingham
  • GSK Investigational Site - Jasper
  • GSK Investigational Site - Tuscaloosa

Florida

  • GSK Investigational Site - Boca Raton
  • GSK Investigational Site - Largo
  • GSK Investigational Site - Pembroke Pines
  • GSK Investigational Site - St. Petersburg

Arizona

  • GSK Investigational Site - Phoenix
  • GSK Investigational Site - Phoenix

Arkansas

  • GSK Investigational Site - Little Rock

Colorado

  • GSK Investigational Site - Aurora

Connecticut

  • GSK Investigational Site - Danbury

Trial Details

FieldValue
Enrollment Target 360 participants
Start Date 2003-08
Est. Completion 2004-05
Phase Phase 3
GlaxoSmithKline

1,345 total trials

What the finished NCT00363857 record still lists

NCT00363857 is an interventional study that assigns participants to a tested intervention. The registered 360 participants enrollment target is mid-sized for trials with a published cap, above the 71-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (407% higher).

The record links to 2 conditions, with Restless Legs Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Ropinirole is the first listed.

NCT00363857 names 20 study sites across 7 states, led by California, Alabama, Florida.

Frequently Asked Questions

What is clinical trial NCT00363857 about?

NCT00363857 is a clinical study titled "A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome". A 14-Week clinical research study to compare the effectiveness and safety of ropinirole and placebo (an inactive sugar pill) in the treatment of patients with Restless Legs Syndrome (RLS) in the United States.

What is the current status of trial NCT00363857?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 360 participants. The study started on 2003-08. Estimated completion is 2004-05.

What conditions does trial NCT00363857 study?

This clinical trial studies the following conditions: Restless Legs Syndrome, Restless Legs Syndrome (RLS).

What interventions are being tested in trial NCT00363857?

The interventions under investigation include: Ropinirole (DRUG).

Who is sponsoring clinical trial NCT00363857?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00363857 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Restless Legs Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00363857's enrollment target sits among peer trials

360 1st of 14 higher than 14 of 14 other Restless Legs Syndrome trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Restless Legs Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02747836 · 360 participants

    Ultrasound Analysis of Human Carpal Tunnel System

  • NCT04089046 · 360 participants · NA

    Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)

  • NCT04130503 · 360 participants · NA

    The Recovery in Stroke Using PAP Study

  • NCT04160000 · 360 participants · Phase 4

    Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00363857, the US trial registry maintained by the National Library of Medicine. NCT00363857 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.